Asthma is a new Decision Resources study that identifies evolving market trends and the opportunities they will create for developers of asthma therapies. The most significant market-driving factor is the increasing prevalence of asthma, predicted to reach 60.4 million in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) by 2010. These and other trends outlined in this study indicate that the asthma is a lucrative area of drug development.
Two theories have been put forth to account for this rise in prevalence. The urbanization model proposes that greater exposure to allergens in modern indoor environments contributes to the development of asthma. The allergic sensitization model attributes the increase in asthma cases to a reduction in exposure to childhood infections (primarily owing to vaccination programs). Whatever its cause, the increase in asthma prevalence is reason for considerable public health concern because asthma leads to significant morbidities. In the United States, for example, asthma accounts for more than 450,000 hospitalizations, 1.9 million emergency room visits, and 5,000 deaths each year, according to the Centers for Disease Control and Prevention.
Sales of drugs for the treatment of asthma in the major pharmaceutical markets totaled $4.8 billion in 2000. We expect that asthma sales will reach $9.8 billion in 2010. In addition to rising prevalence rates, the following trends in the clinical management of asthma will contribute to market growth:
-- Guidelines outlined by the Global Initiative for Asthma (GINA) have recommended the use of inhaled corticosteroids in cases of mild, moderate, and severe persistent asthma. -- The use of leukotriene antagonists, which were introduced in the late 1990s, is growing steadily in the major pharmaceutical markets. -- Adoption of combination agents (i.e., GlaxoSmithKline's Advair/Seretide and AstraZeneca's Symbicort) is likely to increase the total percentage of patients treated with inhaled corticosteroids. -- Expensive novel agents in clinical development, such as anticytokine agents and anti-IgE monoclonal antibodies are likely to contribute significantly to sales growth.
Asthma offers invaluable strategic intelligence for companies competing in this market. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org. In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,